ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past ...

AbbVie’s latest valuation update comes with only a marginal trim to its fair value estimate, shifting from about US$244.68 to ...

April 23 (Reuters) - AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, ...

In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy. Dermatologists seem to be on board with that shift, a good ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sales of Skyrizi and Rinvoq ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

AbbVie has received good news from the European Medicines Agency for a new use of its anti-inflammation drug Skyrizi, one of the best-selling products in its portfolio, now that blockbuster drug ...

Crohn’s disease can be treated with medications that control inflammation and reduce the frequency of flareups for the intestinal disorder. These treatments include biologic drugs that target certain ...